The telehealth company has been selling a copycat version of a popular obesity drug during the recent shortage.
Shares tumbled 21% to $52.22. Over the last year, the stock has surged more than 450%.
Hims & Hers Health Inc. has acquired a California-based manufacturing facility to expand its range of peptide treatments, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback